Advertisement

Ads Placeholder
Loading...

Vivoryon Therapeutics N.V.

VVY.ASβ€’EURONEXT
Healthcare
Biotechnology
€1.33
€0.01(0.76%)
U.S. Market opens in 55h 44m

VVY.AS News Today: Stay Updated with the Latest Vivoryon Therapeutics N.V. News in Real Time

Find VVY.AS news now at Meyka AI. Stay informed with the latest Vivoryon Therapeutics N.V. stocks updates, including price news, market analysis, and expert insights.

ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook
πŸ“… 2 hours ago

ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook

ITRM stock closed at $0.03 on 03 Apr 2026 after Q4 2025 results. Read Meyka AI earnings spotlight and short-term outlook for ITRM stock

Read more
BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026
πŸ“… 1 day ago

BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026

BTIG maintains Buy on ALDX; ALDX analyst rating reviewed after Mar 17, 2026 note

Read more
Pre-Market: MMTX.SW stock rises 8.02% on SIX, watch volume for follow-through
πŸ“… 2 days ago

Pre-Market: MMTX.SW stock rises 8.02% on SIX, watch volume for follow-through

MMTX.SW stock climbs 8.02% pre-market on SIX to CHF 0.35; technical oversold signals and Meyka AI forecast highlight near-term upside

Read more
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
πŸ“… 2 days ago

Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026

Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+

Read more
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
πŸ“… 2 days ago

Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026

PTGX analyst rating update: Jefferies, Johnson Rice maintain Buy; PT $121 and royalty model cited

Read more
CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal
πŸ“… 3 days ago

CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal

Pre-market: CHM.AX stock jumps 100% to A$0.002 on ASX. We analyse drivers, valuation and Meyka AI forecast

Read more
CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026
πŸ“… 4 days ago

CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026

RLF.SW stock intraday: CHF2.885, oversold bounce setup on SIX. Meyka AI forecast and technical outlook for Relief Therapeutics

Read more
ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume
πŸ“… 4 days ago

ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume

ITRM stock down 66% intraday on NASDAQ 30 Mar 2026 with huge volume; short-term outlook and Meyka AI forecast compare risks and upside

Read more
NITI Aayog March 29: Gut Health Warning Puts Probiotics, Digital Care in Focus
πŸ“… 6 days ago

NITI Aayog March 29: Gut Health Warning Puts Probiotics, Digital Care in Focus

NITI Aayog probiotics warning spotlights gut health, evidence-based products, digital health India, and generic medicines policy. We map investor catalysts, risks, and policy signals for India’s nutri

Read more

VVY.AS News FAQ